JP2005041851A5 - - Google Patents

Download PDF

Info

Publication number
JP2005041851A5
JP2005041851A5 JP2003300563A JP2003300563A JP2005041851A5 JP 2005041851 A5 JP2005041851 A5 JP 2005041851A5 JP 2003300563 A JP2003300563 A JP 2003300563A JP 2003300563 A JP2003300563 A JP 2003300563A JP 2005041851 A5 JP2005041851 A5 JP 2005041851A5
Authority
JP
Japan
Prior art keywords
supplement
absorption
utilization rate
ascorbic acid
increased
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003300563A
Other languages
Japanese (ja)
Other versions
JP4569802B2 (en
JP2005041851A (en
Filing date
Publication date
Application filed filed Critical
Priority to JP2003300563A priority Critical patent/JP4569802B2/en
Priority claimed from JP2003300563A external-priority patent/JP4569802B2/en
Publication of JP2005041851A publication Critical patent/JP2005041851A/en
Publication of JP2005041851A5 publication Critical patent/JP2005041851A5/ja
Application granted granted Critical
Publication of JP4569802B2 publication Critical patent/JP4569802B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Description

この測定結果によると、通常、水に溶けやすいため吸収は早いが体外への排出も早いVCについては、被倹者によって増減にばらつきがあるだけでなく時間が経過するにしたがいその血中濃度、増加率ともに低下しているサプリメントB(表3)に対し、本発明に係るサプリメントA(表1)では時間が経過してもいずれの値も増加している。これは、サプリメントBのようにL−アスコルビン酸またはL−アスコルビン酸Naとして吸収するより、サプリメントAのようにL−アスコルビン酸Ca,Mg,K,Naの総合塩にして摂取したほうが吸収の促進を図ることができるだけでなく体内保有量も多くなり、結果的には排出が少なくなって利用率も上がることを示している。
また、VB2についても、サプリメントA(表2)、サプリメントB(表4)ともに前述のVCと同様の傾向を示しているので、サプリメントAの吸収促進および利用率の向上を図ることができることを示している。なお、VB2は通常、黄色の色素が濃く尿とともに排泄されてしまうが、サプリメントAのようにイオン化ミネラル結合型にすると、尿色素も薄く臭いもわずかとなり、排泄も順延されて体内利用率が多くなることにつながる。
この事実から、本発明に係るサプリメントAは、サプリメントBに比較すると、VCやVB2などビタミンの吸収を促進するとともに体内利用率を高めることができ、同量を摂取した場合は利用効率が向上して長時間にわたり効果を得られるが確認された。
According to this measurement result, VC is normally absorbed easily because it is easily dissolved in water, but it is not only variably increased and decreased depending on the subject, but also its blood concentration as time passes. In contrast to the supplement B (Table 3), in which the increase rate is both decreasing, in the supplement A (Table 1) according to the present invention, both values are increased over time. This is because absorption of L-ascorbic acid Ca, Mg, K, Na as a supplemental salt, such as supplement A, promotes absorption rather than absorption as L-ascorbic acid or L-ascorbic acid Na, as in supplement B. In addition to being able to achieve this, the amount in the body increases, and as a result, the discharge is reduced and the utilization rate is increased.
Also, regarding VB2, supplement A (Table 2) and supplement B (Table 4) both show the same tendency as VC described above, indicating that absorption of Supplement A can be promoted and the utilization rate can be improved. ing. VB2 usually has a yellow pigment that is excreted with urine, but when supplemented with ionized minerals like supplement A, the urine pigment is thin and has a slight odor, and excretion is postponed, resulting in a high utilization rate in the body. Will lead to
From this fact, the supplement A according to the present invention can promote the absorption of vitamins such as VC and VB2 and increase the in-vivo utilization rate compared with the supplement B, and the utilization efficiency is improved when the same amount is ingested. It was confirmed that the effect can be obtained for a long time.

JP2003300563A 2003-07-23 2003-07-23 Method for producing an ionized mineral-binding supplement mainly composed of vitamins Expired - Lifetime JP4569802B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2003300563A JP4569802B2 (en) 2003-07-23 2003-07-23 Method for producing an ionized mineral-binding supplement mainly composed of vitamins

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2003300563A JP4569802B2 (en) 2003-07-23 2003-07-23 Method for producing an ionized mineral-binding supplement mainly composed of vitamins

Publications (3)

Publication Number Publication Date
JP2005041851A JP2005041851A (en) 2005-02-17
JP2005041851A5 true JP2005041851A5 (en) 2006-05-18
JP4569802B2 JP4569802B2 (en) 2010-10-27

Family

ID=34269087

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003300563A Expired - Lifetime JP4569802B2 (en) 2003-07-23 2003-07-23 Method for producing an ionized mineral-binding supplement mainly composed of vitamins

Country Status (1)

Country Link
JP (1) JP4569802B2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101119991B (en) 2005-02-18 2012-01-25 田边三菱制药株式会社 Salt of proline derivative, solvate thereof, and production method thereof
JP5028609B2 (en) * 2006-02-13 2012-09-19 眞 八藤 Method for producing iron supplement composition
JP2008035714A (en) * 2006-08-01 2008-02-21 Wakasa Seikatsu:Kk Health food
JP5069195B2 (en) * 2008-08-26 2012-11-07 眞 八藤 Salt composition solution
JP5735906B2 (en) * 2011-12-28 2015-06-17 八藤 眞 Alcohol preparation for noodle production
JP6211905B2 (en) * 2013-11-22 2017-10-11 八藤 眞 Method for producing ionized metal liquid capable of binding to nutritional components

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9105986A (en) * 1990-02-05 1992-11-10 Univ Texas TIME-RELEASE FORMULATION OF VITAMINS, MINERALS AND OTHER BENEFICIAL SUPPLEMENTS
US5292729A (en) * 1992-08-14 1994-03-08 Albion International, Inc. II-bond aromatic vitamin chelates
DK1155620T3 (en) * 2000-05-18 2005-12-05 Mega Healthcare As Q Dietary supplement with vitamins, minerals and polyunsaturated fatty acids
JP2002369663A (en) * 2001-06-15 2002-12-24 Kenko Hyakunijussai:Kk Base food for health care and combined health promotion food

Similar Documents

Publication Publication Date Title
HRP20211077T1 (en) Sodium nitrite-containing pharmaceutical compositions
RU2008118101A (en) MIXTURE OF IRON AND COPPER SALTS, MASKING METAL TASTE
EP1209986A1 (en) Metal-containing compositions, preparations and uses
KR20110128329A (en) Phosphate adsorbent
RU2009115791A (en) MIXTURE OF IRON AND COPPER SALTS, MASKING METAL TASTE
WO2004017998A3 (en) Topical emulsion- gel composition comprising diclofenac sodium
JP2005041851A5 (en)
JPWO2010041647A1 (en) Endurance improver, fatigue inhibitor, or fatigue recovery agent comprising an amino acid composition as an active ingredient
JP2009514786A5 (en)
JP2003508467A5 (en)
RU2006109966A (en) YANTASTIM-S DRUG FOR THERAPY AND PREVENTION OF ANIMAL INFECTIOUS DISEASES
DS AMALGAMATION OF AYURVEDIC CONCEPT WITH MODERN MEDICAL PRACTICE TO MANAGE KIDNEY STONE DISEASE (UROLITHIASIS): AN ABBREVIATED REVIEW.
US7910137B2 (en) Metal carnitine chelates
JPS58165774A (en) Drink composition
Ulemale et al. Fluorosis in cattle
Lina et al. The role of alkalizing and neutral potassium salts in urinary bladder carcinogenesis in rats
JPS60197624A (en) Urine-alkalizing food composition
TWI312340B (en)
JP3024896B2 (en) Anemia ameliorating material
JP2003321371A (en) Diuretic
ATE259778T1 (en) NON-HYGROSCOPIC SALTS OF ACTIVE INGREDIENTS HAVING THERAPEUTIC AND/OR NUTRITIONAL PROPERTIES AND ORAL COMPOSITIONS CONTAINING SAME
JP2004166690A (en) Zinc-containing product having antioxidative effect
JP5915013B2 (en) Oral solution
JP2001151682A (en) Substance for activating biofunction
Kaniovska et al. SELENIUM, A TRACE ELEMENT, AND POSSIBILITIES OF ITS APPLICATION IN PATHOLOGY OF INTERNAL ORGANS